Methods for the identification of vascular markers in health and disease: From the bench to the clinic

Journal of Proteomics

Volumn 73, Issue 11, 2010, Pages 2219-2229

  Roesli, Christoph ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Antibody; Biomarker; Discovery; Proteomics; Vascular targeting

Indexed keywords

ABEGRIN; ANTINEOPLASTIC AGENT; ARENAGYR; BAVITUXIMAB; BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; CARBOPLATIN; D 93 ANTIBODY; DACARBAZINE; DOCETAXEL; ETARACIZUMAB; FIBRONECTIN; HU 177 ANTIBODY; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN M; MELANOMA ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591; MONOCLONAL ANTIBODY LM 609; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PACLITAXEL; PEPTIDE LIBRARY; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN GW 112; PROTEIN MG 50; TENASCIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2; VERSICAN;

ADVANCED CANCER; ANGIOGENESIS; BIOPANNING; BIOTINYLATION; BREAST CANCER; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG NON SMALL CELL CANCER; MATERIAL COATING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MELANOMA; METASTASIS; MOLECULAR IMAGING; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PEPTIDE MAPPING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SOLID TUMOR;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PHARMACOLOGY, CLINICAL; PROTEOMICS; TECHNOLOGY, PHARMACEUTICAL; VASCULAR DISEASES;

EID: 77957192187     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2010.05.017     Document Type: Review

References (123)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002, 29:15-18.
2. de la Torre J.C. Cerebrovascular and cardiovascular pathology in Alzheimer's disease. Int Rev Neurobiol 2009, 84:35-48.
3. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 2007, 6:273-286.
4. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005, 69(Suppl 3):11-16.
5. Burrows F.J., Thorpe P.E. Vascular targeting-a new approach to the therapy of solid tumors. Pharmacol Ther 1994, 64:155-174.
6. Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993, 66:181-196.
7. Neri D., Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005, 5:436-446.
8. Bosslet K., Straub R., Blumrich M., Czech J., Gerken M., Sperker B., et al. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 1998, 58:1195-1201.
9. Neri D., Carnemolla B., Nissim A., Leprini A., Querze G., Balza E., et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 1997, 15:1271-1275.
10. Birchler M., Viti F., Zardi L., Spiess B., Neri D. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat Biotechnol 1999, 17:984-988.
11. Matter C.M., Schuler P.K., Alessi P., Meier P., Ricci R., Zhang D., et al. Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ Res 2004, 95:1225-1233.
12. Schwager K., Kaspar M., Bootz F., Marcolongo R., Paresce E., Neri D., et al. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther 2009, 11:R142.
13. Trachsel E., Kaspar M., Bootz F., Detmar M., Neri D. A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo. J Investig Dermatol 2007, 127:881-886.
14. von Lukowicz T., Silacci M., Wyss M.T., Trachsel E., Lohmann C., Buck A., et al. Human antibody against C domain of tenascin-C visualizes murine atherosclerotic plaques ex vivo. J Nucl Med 2007, 48:582-587.
15. Walsh G. Biopharmaceutical benchmarks 2006. Nat Biotechnol 2006, 24:769-776.
16. Dennis M.S., Jin H., Dugger D., Yang R., McFarland L., Ogasawara A., et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 2007, 67:254-261.
17. Thurber G.M., Zajic S.C., Wittrup K.D. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med 2007, 48:995-999.
18. Halin C., Niesner U., Villani M.E., Zardi L., Neri D. Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins. Int J Cancer 2002, 102:109-116.
19. Schliemann C., Neri D. Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta 2007, 1776:175-192.
20. Elschenbroich S., Kim Y., Medin J.A., Kislinger T. Isolation of cell surface proteins for mass spectrometry-based proteomics. Expert Rev Proteomics 2010, 7:141-154.
21. Strassberger V, Fugmann T, Neri D, Roesli C. Chemical proteomic and bioinformatic strategies for the identification and quantification of vascular antigens in cancer. J Proteomics 2010, doi:10.1016/j.jprot.2010.05.018.
22. Herbert J.M., Stekel D., Sanderson S., Heath V.L., Bicknell R. A novel method of differential gene expression analysis using multiple cDNA libraries applied to the identification of tumour endothelial genes. BMC Genomics 2008, 9:153.
23. St Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., et al. Genes expressed in human tumor endothelium. Science (New York) 2000, 289:1197-1202.
24. Zardi L., Carnemolla B., Siri A., Petersen T.E., Paolella G., Sebastio G., et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 1987, 6:2337-2342.
25. Carnemolla B., Balza E., Siri A., Zardi L., Nicotra M.R., Bigotti A., et al. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 1989, 108:1139-1148.
26. Carnemolla B., Leprini A., Allemanni G., Saginati M., Zardi L. The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence. J Biol Chem 1992, 267:24689-24692.
27. Castellani P., Viale G., Dorcaratto A., Nicolo G., Kaczmarek J., Querze G., et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994, 59:612-618.
28. Kaczmarek J., Castellani P., Nicolo G., Spina B., Allemanni G., Zardi L. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer 1994, 59:11-16.
29. Carnemolla B., Neri D., Castellani P., Leprini A., Neri G., Pini A., et al. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Cancer 1996, 68:397-405.
30. Giovannoni L., Viti F., Zardi L., Neri D. Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening. Nucleic Acids Res 2001, 29:E27.
31. Pini A., Viti F., Santucci A., Carnemolla B., Zardi L., Neri P., et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998, 273:21769-21776.
32. Sommavilla R., Lovato V., Villa A., Sgier D., Neri D. Design and construction of a naive mouse antibody phage display library. J Immunol Meth 2010, 353:31-43.
33. Castellani P., Borsi L., Carnemolla B., Biro A., Dorcaratto A., Viale G.L., et al. Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol 2002, 161:1695-1700.
34. Pedretti M., Rancic Z., Soltermann A., Herzog B.A., Schliemann C., Lachat M., et al. Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: three clinical-grade fully human antibodies. Atherosclerosis 2010, 208:382-389.
35. Sauer S., Erba P.A., Petrini M., Menrad A., Giovannoni L., Grana C., et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009, 113:2265-2274.
36. Schliemann C., Palumbo A., Zuberbuhler K., Villa A., Kaspar M., Trachsel E., et al. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 2009, 113:2275-2283.
37. Schliemann C., Wiedmer A., Pedretti M., Szczepanowski M., Klapper W., Neri D. Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res 2009, 33:1718-1722.
38. Winter G., Griffiths A.D., Hawkins R.E., Hoogenboom H.R. Making antibodies by phage display technology. Annu Rev Immunol 1994, 12:433-455.
39. Peters J.H., Trevithick J.E., Johnson P., Hynes R.O. Expression of the alternatively spliced EIIIB segment of fibronectin. Cell Adhes Commun 1995, 3:67-89.
40. Balza E., Castellani P., Zijlstra A., Neri D., Zardi L., Siri A. Lack of specificity of endoglin expression for tumor blood vessels. Int J Cancer 2001, 94:579-585.
41. Duff S.E., Li C., Garland J.M., Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003, 17:984-992.
42. Burrows F.J., Derbyshire E.J., Tazzari P.L., Amlot P., Gazdar A.F., King S.W., et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995, 1:1623-1634.
43. Ran S., Downes A., Thorpe P.E. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 2002, 62:6132-6140.
44. Luster T.A., He J., Huang X., Maiti S.N., Schroit A.J., de Groot P.G., et al. Plasma protein beta-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells. J Biol Chem 2006, 281:29863-29871.
45. Soares M.M., King S.W., Thorpe P.E. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med 2008, 14:1357-1362.
46. Jennewein M., Lewis M.A., Zhao D., Tsyganov E., Slavine N., He J., et al. Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine. Clin Cancer Res 2008, 14:1377-1385.
47. Smith G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science (New York) 1985, 228:1315-1317.
48. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (New York) 1998, 279:377-380.
49. Pasqualini R., Ruoslahti E. Tissue targeting with phage peptide libraries. Mol Psychiatry 1996, 1:423.
50. Pasqualini R., Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996, 380:364-366.
51. Pasqualini R., Koivunen E., Kain R., Lahdenranta J., Sakamoto M., Stryhn A., et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000, 60:722-727.
52. Pasqualini R., Koivunen E., Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997, 15:542-546.
53. Laakkonen P., Zhang L., Ruoslahti E. Peptide targeting of tumor lymph vessels. Ann NY Acad Sci 2008, 1131:37-43.
54. Valadon P., Garnett J.D., Testa J.E., Bauerle M., Oh P., Schnitzer J.E. Screening phage display libraries for organ-specific vascular immunotargeting in vivo. Proc Natl Acad Sci USA 2006, 103:407-412.
55. Chaney L.K., Jacobson B.S. Coating cells with colloidal silica for high yield isolation of plasma membrane sheets and identification of transmembrane proteins. J Biol Chem 1983, 258:10062-10072.
56. Oh P., Li Y., Yu J., Durr E., Krasinska K.M., Carver L.A., et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004, 429:629-635.
57. Schnitzer J.E., McIntosh D.P., Dvorak A.M., Liu J., Oh P. Separation of caveolae from associated microdomains of GPI-anchored proteins. Science (New York) 1995, 269:1435-1439.
58. Rybak J.N., Ettorre A., Kaissling B., Giavazzi R., Neri D., Elia G. In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Meth 2005, 2:291-298.
59. Roesli C., Neri D., Rybak J.N. In vivo protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature. Nat Protoc 2006, 1:192-199.
60. Kamada H., Fugmann T., Neri D., Roesli C. Improved protein sequence coverage by on resin deglycosylation and cysteine modification for biomarker discovery. Proteomics 2009, 9:783-787.
61. Fugmann T., Neri D., Roesli C. DeepQuanTR: MALDI-MS-based label-free quantification of proteins in complex biological samples. Proteomics 2010, [Electronic publication ahead of print].
62. Borgia B., Roesli C., Fugmann T., Schliemann C., Cesca M., Neri D., et al. A proteomic approach for the identification of vascular markers of liver metastasis. Cancer Res 2010, 70:309-318.
63. Rybak J.N., Roesli C., Kaspar M., Villa A., Neri D. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res 2007, 67:10948-10957.
64. Schliemann C., Roesli C., Kamada H., Borgia B., Fugmann T., Klapper W., et al. In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy. Blood 2010, 115:736-744.
65. Castronovo V., Waltregny D., Kischel P., Roesli C., Elia G., Rybak J.N., et al. A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics 2006, 5:2083-2091.
66. Conrotto P., Roesli C., Rybak J., Kischel P., Waltregny D., Neri D., et al. Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int J Cancer 2008, 123:2856-2864.
67. Roesli C, Fugmann T, Borgia B, Schliemann C, Neri D, Jucker M. The accessible cerebral vascular proteome in a mouse model of Alzheimer's disease. submitted.
68. Fugmann T, Borgia B, Hamar P, Neri D, Roesli C. Proteomic identification of accessible proteins in a rat model of diabetic nephropathy reveals vanin-1 as a marker of kidney damage. submitted.
69. Scheurer S.B., Rybak J.N., Roesli C., Brunisholz R.A., Potthast F., Schlapbach R., et al. Identification and relative quantification of membrane proteins by surface biotinylation and two-dimensional peptide mapping. Proteomics 2005, 5:2718-2728.
70. Roesli C., Borgia B., Schliemann C., Gunthert M., Wunderli-Allenspach H., Giavazzi R., et al. Comparative analysis of the membrane proteome of closely related metastatic and nonmetastatic tumor cells. Cancer Res 2009, 69:5406-5414.
71. Roesli C., Mumprecht V., Neri D., Detmar M. Identification of the surface-accessible, lineage-specific vascular proteome by two-dimensional peptide mapping. FASEB J 2008, 22:1933-1944.
72. Elia G. Biotinylation reagents for the study of cell surface proteins. Proteomics 2008, 8:4012-4024.
73. Bond M.R., Kohler J.J. Chemical methods for glycoprotein discovery. Curr Opin Chem Biol 2007, 11:52-58.
74. Vosseller K., Trinidad J.C., Chalkley R.J., Specht C.G., Thalhammer A., Lynn A.J., et al. O-linked N-acetylglucosamine proteomics of postsynaptic density preparations using lectin weak affinity chromatography and mass spectrometry. Mol Cell Proteomics 2006, 5:923-934.
75. Khidekel N., Ficarro S.B., Peters E.C., Hsieh-Wilson L.C. Exploring the O-GlcNAc proteome: direct identification of O-GlcNAc-modified proteins from the brain. Proc Natl Acad Sci USA 2004, 101:13132-13137.
76. Schiess R., Mueller L.N., Schmidt A., Mueller M., Wollscheid B., Aebersold R. Analysis of cell surface proteome changes via label-free, quantitative mass spectrometry. Mol Cell Proteomics 2009, 8:624-638.
77. Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M., Schiess R., et al. Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. Nat Biotechnol 2009, 27:378-386.
78. Zhang H., Li X.J., Martin D.B., Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003, 21:660-666.
79. Klement E., Lipinszki Z., Kupihar Z., Udvardy A., Medzihradszky K.F. Enrichment of O-GlcNAc modified proteins by the periodate oxidation-hydrazide resin capture approach. J Proteome Res 2010, 9:2200-2206.
80. Rudin M. Noninvasive structural, functional, and molecular imaging in drug development. Curr Opin Chem Biol 2009, 13:360-371.
81. Tijink B.M., Perk L.R., Budde M., Stigter-van Walsum M., Visser G.W., Kloet R.W., et al. (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging 2009, 36:1235-1244.
82. Borjesson P.K., Jauw Y.W., Boellaard R., de Bree R., Comans E.F., Roos J.C., et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res 2006, 12:2133-2140.
83. Ntziachristos V., Yodh A.G., Schnall M., Chance B. Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc Natl Acad Sci USA 2000, 97:2767-2772.
84. Weissleder R., Pittet M.J. Imaging in the era of molecular oncology. Nature 2008, 452:580-589.
85. Birchler M., Neri G., Tarli L., Halin C., Viti F., Neri D. Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers. J Immunol Meth 1999, 231:239-248.
86. Trachsel E., Bootz F., Silacci M., Kaspar M., Kosmehl H., Neri D. Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther 2007, 9:R9.
87. Vogel C.A., Galmiche M.C., Westermann P., Sun L.Q., Pelegrin A., Folli S., et al. Carcinoembryonic antigen expression, antibody localisation and immunophotodetection of human colon cancer liver metastases in nude mice: a model for radioimmunotherapy. Int J Cancer 1996, 67:294-302.
88. Birchler M.T., Thuerl C., Schmid D., Neri D., Waibel R., Schubiger A., et al. Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenetic antibody fragment. Otolaryngol Head Neck Surg 2007, 136:543-548.
89. Santimaria M., Moscatelli G., Viale G.L., Giovannoni L., Neri G., Viti F., et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003, 9:571-579.
90. Sauer S., Erba P.A., Petrini M., Menrad A., Giovannoni L., Grana C., et al. Expression of the oncofetal ED-B containing fibronectin isoform in hematologic tumors enables ED-B targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009, 113:2265-2274.
91. Berndorff D., Borkowski S., Sieger S., Rother A., Friebe M., Viti F., et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res 2005, 11:7053s-7063s.
92. Borsi L., Balza E., Bestagno M., Castellani P., Carnemolla B., Biro A., et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002, 102:75-85.
93. Tijink B.M., Neri D., Leemans C.R., Budde M., Dinkelborg L.M., Stigter-van Walsum M., et al. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 2006, 47:1127-1135.
94. Joseph S., Olbrich C., Kirsch J., Hasbach M., Briel A., Schirner M. A real-time in vitro assay for studying functional characteristics of target-specific ultrasound contrast agents. Pharm Res 2004, 21:920-926.
95. Alonso A., Della Martina A., Stroick M., Fatar M., Griebe M., Pochon S., et al. Molecular imaging of human thrombus with novel abciximab immunobubbles and ultrasound. Stroke Journal Cerebral Circulation 2007, 38:1508-1514.
96. Jun H.Y., Park S.H., Kim H.S., Yoon K.H. Long residence time of ultrasound microbubbles targeted to integrin in murine tumor model. Acad Radiol 2010, 17:54-60.
97. Pochon S., Tardy I., Bussat P., Bettinger T., Brochot J., von Wronski M., et al. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis. Invest Radiol 2010, 45:89-95.
98. Gregorc V., Citterio G., Vitali G., Spreafico A., Scifo P., Borri A., et al. Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur J Cancer 2010, 46:198-206.
99. Gregorc V., Santoro A., Bennicelli E., Punt C.J., Citterio G., Timmer-Bonte J.N., et al. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer 2009, 101:219-224.
100. van Laarhoven H.W., Fiedler W., Desar I.M., van Asten J.J., Marreaud S., Lacombe D., et al. Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041). Clin Cancer Res 2010, 16:1315-1323.
101. Schnitzer J.E., Oh P., Jacobson B.S., Dvorak A.M. Caveolae from luminal plasmalemma of rat lung endothelium: microdomains enriched in caveolin, Ca(2+)-ATPase, and inositol trisphosphate receptor. Proc Natl Acad Sci USA 1995, 92:1759-1763.
102. Ahlskog J.K., Schliemann C., Marlind J., Qureshi U., Ammar A., Pedley R.B., et al. Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br J Cancer 2009, 101:645-657.
103. Pfaffen S., Hemmerle T., Weber M., Neri D. Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3. Exp Cell Res 2010, 316:836-847.
104. Sgier D., Zuberbuehler K., Pfaffen S., Neri D. Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA. Protein Eng Des Sel 2010, 23:261-269.
105. Balza E., Carnemolla B., Mortara L., Castellani P., Soncini D., Accolla R.S., et al. Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha. Int J Cancer 2010, 127:101-110.
106. Balza E., Mortara L., Sassi F., Monteghirfo S., Carnemolla B., Castellani P., et al. Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin Cancer Res 2006, 12:2575-2582.
107. Borsi L., Balza E., Carnemolla B., Sassi F., Castellani P., Berndt A., et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003, 102:4384-4392.
108. Carnemolla B., Borsi L., Balza E., Castellani P., Meazza R., Berndt A., et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002, 99:1659-1665.
109. Ebbinghaus C., Ronca R., Kaspar M., Grabulovski D., Berndt A., Kosmehl H., et al. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer 2005, 116:304-313.
110. Fabbrini M., Trachsel E., Soldani P., Bindi S., Alessi P., Bracci L., et al. Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate. Int J Cancer 2006, 118:1805-1813.
111. Gafner V., Trachsel E., Neri D. An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int J Cancer 2006, 119:2205-2212.
112. Halin C., Gafner V., Villani M.E., Borsi L., Berndt A., Kosmehl H., et al. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 2003, 63:3202-3210.
113. Nilsson F., Kosmehl H., Zardi L., Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001, 61:711-716.
114. Brooks P.C., Stromblad S., Klemke R., Visscher D., Sarkar F.H., Cheresh D.A. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995, 96:1815-1822.
115. Hersey P., Sosman J., O'Day S., Richards J., Bedikian A., Gonzalez R., et al. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer 2010, 116:1526-1534.
116. Silver D.A., Pellicer I., Fair W.R., Heston W.D., Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997, 3:81-85.
117. Tagawa S.T., Beltran H., Vallabhajosula S., Goldsmith S.J., Osborne J., Matulich D., et al. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 2010, 116:1075-1083.
118. Wolf P., Freudenberg N., Buhler P., Alt K., Schultze-Seemann W., Wetterauer U., et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate 2010, 70:562-569.
119. Brekken R.A., Thorpe P.E. VEGF-VEGF receptor complexes as markers of tumor vascular endothelium. J Control Release 2001, 74:173-181.
120. Brekken R.A., Huang X., King S.W., Thorpe P.E. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 1998, 58:1952-1959.
121. Roland C.L., Dineen S.P., Lynn K.D., Sullivan L.A., Dellinger M.T., Sadegh L., et al. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 2009, 8:1761-1771.
122. Cretu A., Roth J.M., Caunt M., Akalu A., Policarpio D., Formenti S., et al. Disruption of endothelial cell interactions with the novel HU177 cryptic collagen epitope inhibits angiogenesis. Clin Cancer Res 2007, 13:3068-3078.
123. Freimark B., Clark D., Pernasetti F., Nickel J., Myszka D., Baeuerle P.A., et al. Targeting of humanized antibody D93 to sites of angiogenesis and tumor growth by binding to multiple epitopes on denatured collagens. Mol Immunol 2007, 44:3741-3750.